C50.929 - Malignant neoplasm of unspecified site of unspecified male breast
ICD-10: | C50.929 |
Short Description: | Malignant neoplasm of unsp site of unspecified male breast |
Long Description: | Malignant neoplasm of unspecified site of unspecified male breast |
Status: | Valid for Submission |
Version: | ICD-10-CM 2023 |
Code Classification: |
C50.929 is a billable ICD-10 code used to specify a medical diagnosis of malignant neoplasm of unspecified site of unspecified male breast. The code is valid during the fiscal year 2023 from October 01, 2022 through September 30, 2023 for the submission of HIPAA-covered transactions.
This code is applicable to male patients only. It is clinically and virtually impossible to use this code on a non-male patient.
Unspecified diagnosis codes like C50.929 are acceptable when clinical information is unknown or not available about a particular condition. Although a more specific code is preferable, unspecified codes should be used when such codes most accurately reflect what is known about a patient's condition. Specific diagnosis codes should not be used if not supported by the patient's medical record.
Approximate Synonyms
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Adenocarcinoma of breast
- Blood/lymphatic vessel invasion by tumor absent
- Blood/lymphatic vessel invasion by tumor indeterminate
- Blood/lymphatic vessel invasion by tumor present
- Carcinoma of bone, connective tissue, skin and breast
- Carcinoma of breast
- Carcinoma of male breast
- Carcinoma of salivary gland type of breast
- Eccrine ductal carcinoma
- Familial cancer of breast
- Germline BRCA-mutated, HER2-negative metastatic breast cancer
- HER2-positive carcinoma of breast
- Hormone receptor negative neoplasm
- Hormone receptor positive malignant neoplasm of breast
- Hormone receptor positive tumor
- Human epidermal growth factor 2 negative carcinoma of breast
- Infiltrating ductal carcinoma of breast, stage 1
- Infiltrating ductal carcinoma of breast, stage 2
- Infiltrating ductal carcinoma of breast, stage 3
- Infiltrating ductal carcinoma of breast, stage 4
- Infiltrating lobular carcinoma of breast
- Inflammatory carcinoma of breast
- Invasive carcinoma of breast
- Local recurrence of malignant tumor of breast
- Locally advanced breast cancer
- Malignant melanoma of breast
- Malignant neoplasm of bone, connective tissue, skin and breast
- Malignant neoplasm of bone, connective tissue, skin and breast
- Malignant neoplasm of ectopic site of male breast
- Malignant neoplasm of male breast
- Malignant phyllodes tumor of breast
- Malignant tumor of breast
- Metaplastic carcinoma of breast
- Metastasis from malignant tumor of breast
- Metastatic human epidermal growth factor 2 positive carcinoma of breast
- Mixed ductal and lobular carcinoma of breast
- Mucinous carcinoma of breast
- Neoplasm of breast distant metastasis staging category M0: No clinical or radiographic evidence of distant metastasis
- Neoplasm of breast primary tumor staging category T1c: Tumor >10 mm but <=20 mm in greatest dimension
- Neoplasm of breast primary tumor staging category T1mi: Tumor <=1 mm in greatest dimension
- Neoplasm of breast primary tumor staging category T4: Direct extension to chest wall and/or skin beyond dermis
- Neoplasm of breast primary tumor staging category T4a: Extension to the chest wall, not including only adherence and/or invasion to pectoralis muscle
- Neoplasm of breast primary tumor staging category T4b: Ulceration and/or ipsilateral satellite nodules and/or edema of the skin, excluding inflammatory carcinoma
- Neoplasm of breast primary tumor staging category T4d: Inflammatory carcinoma involving >=1/3 of skin of breast
- Neoplasm of breast primary tumor staging category TX: Primary tumor cannot be assessed
- Neoplasm of breast regional lymph node staging category N0: No regional lymph node metastasis
- Neoplasm of breast regional lymph node staging category N1: Metastasis to movable ipsilateral level I, II axillary lymph node
- Neoplasm of breast regional lymph node staging category N2 as per American Joint Committee on Cancer 7th edition
- Neoplasm of breast regional lymph node staging category pN0 as per American Joint Committee on Cancer 7th edition
- Neoplasm of breast regional lymph node staging category pN0: No regional lymph node metastasis histologically, negative immunohistochemically
- Neoplasm of ectopic male breast tissue
- Phyllodes tumor of breast
- pM0 category
- pM0: No distant metastasis
- pM1: Distant metastasis
- pMX category
- pMX: Distant metastasis cannot be assessed
- pN1: Metastasis in 1 to 3 axillary lymph nodes, and/or in internal mammary nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent
- pN1a category
- pN1a: Metastasis in 1 to 3 axillary lymph nodes
- pN1b category
- pN1b: Metastasis in internal mammary lymph nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent
- pN1c category
- pN1c: Metastasis in 1 to 3 axillary lymph nodes and in internal mammary lymph nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent
- pN1mi
- pN1mi category
- pN1mi category
- pN1mi: Micrometastasis
- pN2: Metastasis in 4 to 9 axillary lymph nodes, or in clinically apparent internal mammary lymph nodes in the absence of axillary lymph node metastasis
- pN2a category
- pN2a: Metastasis in 4 to 9 axillary lymph nodes
- pN2b category
- pN2b: Metastasis in clinically apparent internal mammary lymph nodes in the absence of axillary lymph node metastasis
- pN3a category
- pN3a: Metastasis in 10 or more axillary lymph nodes
- pN3b category
- pN3b: Tumor of breast with metastasis as per AJCC 6th Edition definition
- pN3c category
- pN3c: Metastasis in ipsilateral supraclavicular lymph nodes
- pNX category
- pNX: Regional lymph nodes cannot be assessed
- Primary angiosarcoma of breast
- Primary angiosarcoma of thorax
- Primary angiosarcoma of trunk
- Primary intracystic papillary carcinoma of breast
- Primary invasive pleomorphic lobular carcinoma of breast
- Primary malignant neoplasm of breast
- Primary malignant neoplasm of breast with axillary lymph node invasion
- Primary malignant neoplasm of ectopic male breast tissue
- Primary malignant neoplasm of male breast
- Primary malignant neoplasm of sweat gland
- Primary sarcoma of thorax
- Primary solid papillary carcinoma with invasion of breast
- pT1: Tumor 2 cm or less in greatest dimension
- pT1a: Tumor more than 0.1 cm but not more than 0.5 cm in greatest dimension
- pT1b: Tumor more than 0.5 cm but not more than 1 cm in greatest dimension
- pT1c category
- pT1c: Tumor more than 1 cm but not more than 2 cm in greatest dimension
- pT1mic category
- pT1mic: Microinvasion 0.1 cm or less in greatest dimension
- pT2: Tumor more than 2 cm but not more than 5 cm in greatest dimension
- pT3: Tumor more than 5 cm in greatest dimension
- pT4: Tumor of any size with direct extension to chest wall or skin
- pT4a: Tumor of any size with extension to chest wall, not including pectoralis muscle
- pT4b: Tumor of any size with edema or ulceration of the skin of the breast or satellite skin nodules confined to the same breast
- pT4c category
- pT4c: Tumor of any size with direct extension to chest wall or ulceration of the skin of the breast or satellite skin nodules confined to the same breast
- pT4d category
- pT4d: Inflammatory carcinoma
- Sarcoma of breast
- Sarcoma of breast
- Sarcoma of male breast
- Scirrhous carcinoma of breast
- Secondary malignant neoplasm of axilla
- Secondary malignant neoplasm of axillary lymph nodes
- T1: Breast tumor <= 2 cm in greatest dimension
- T1a: Breast tumor >0.1 cm but <= 0.5 cm in greatest dimension
- T1b: Breast tumor >0.5 cm but <= 1 cm in greatest dimension
- T1c: >1 cm but <= 2 cm in greatest dimension: BREAST: Complete excision less than total mastectomy, total mastectomy, modified radical mastectomy, radical mastectomy
- T1mic: Microinvasion <= 0.1 cm in greatest dimension: BREAST: Complete excision less than total mastectomy, total mastectomy, modified radical mastectomy, radical mastectomy
- T2: Breast tumor > 2 cm but <= 5 cm in greatest dimension
- T3: Breast tumor >5 cm in greatest dimension
- T4: Breast tumor of any size with direct extension to chest wall or skin
- T4a: Breast tumor with extension to chest wall
- T4b: Edema or ulceration of the skin of the breast or satellite skin nodules confined to the same breast
- T4c: Breast tumor, both T4a and T4b
- T4d: Inflammatory carcinoma
- T4d: Inflammatory carcinoma of breast with involvement of skin and chest wall by carcinoma
- Triple-negative breast cancer
Code Edits
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:
- Diagnoses for males only - The Medicare Code Editor detects inconsistencies between a patient’s sex and any diagnosis on the patient’s record, these edits apply to MALES only .
Convert to ICD-9 Code
Source ICD-10 Code | Target ICD-9 Code | |
---|---|---|
C50.929 | 175.9 - Mal neo male breast NEC | |
Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code. |
Patient Education
Male Breast Cancer
Although breast cancer is much more common in women, men can get it too. It happens most often to men between the ages of 60 and 70.
Breast lumps usually aren't cancer. However, most men with breast cancer have lumps. Other breast symptoms can include:
- Dimpled or puckered skin
- A red, scaly nipple or skin
- Fluid discharge
Risk factors for male breast cancer include exposure to radiation, a family history of breast cancer, and having high estrogen levels, which can happen with diseases like cirrhosis or Klinefelter syndrome.
Treatment for male breast cancer is usually a mastectomy, which is surgery to remove the breast. Other treatments include radiation, chemotherapy and/or hormone therapy.
NIH: National Cancer Institute
[Learn More in MedlinePlus]
Breast cancer
Breast cancer is a disease in which certain cells in the breast become abnormal and multiply uncontrollably to form a tumor. Although breast cancer is much more common in women, this form of cancer can also develop in men. In both women and men, the most common form of breast cancer begins in cells lining the milk ducts (ductal cancer). In women, cancer can also develop in the glands that produce milk (lobular cancer). Most men have little or no lobular tissue, so lobular cancer in men is very rare.
In its early stages, breast cancer usually does not cause pain and may exhibit no noticeable symptoms. As the cancer progresses, signs and symptoms can include a lump or thickening in or near the breast; a change in the size or shape of the breast; nipple discharge, tenderness, or retraction (turning inward); and skin irritation, dimpling, redness, or scaliness. However, these changes can occur as part of many different conditions. Having one or more of these symptoms does not mean that a person definitely has breast cancer.
In some cases, cancerous cells can invade surrounding breast tissue. In these cases, the condition is known as invasive breast cancer. Sometimes, tumors spread to other parts of the body. If breast cancer spreads, cancerous cells most often appear in the bones, liver, lungs, or brain. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers.
A small percentage of all breast cancers cluster in families. These cancers are described as hereditary and are associated with inherited gene mutations. Hereditary breast cancers tend to develop earlier in life than noninherited (sporadic) cases, and new (primary) tumors are more likely to develop in both breasts.
[Learn More in MedlinePlus]
Male Breast Cancer Treatment (PDQ®)
Learn about male breast cancer risk factors, symptoms, tests to diagnose, factors affecting prognosis, staging, and treatment.[Learn More in MedlinePlus]
Code History
- FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
- FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
- FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
- FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
- FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
- FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
- FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
- FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)